CoChat

Randomised clinical trials: linaclotide phase 3 studies in IBS ‐C – a prespecified further analysis based on European Medicines Agency‐specified endpoints

Quigley, E. M. M., Tack, J., Chey, W. D., Rao, S. S., Fortea, J., Falques, M., Diaz, C., Shiff, S. J., Currie, M. G., Johnston, J. M. · 2013 · Alimentary Pharmacology & Therapeutics
Cited by 127

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Summary: Background: Treatment options that improve overall symptoms of irritable bowel syndrome with constipation ( IBS ‐C) are lacking. Aim: A prespecified further analysis to evaluate the efficacy and safety of linaclotide, a guanylate cyclase C agonist, in patients with IBS ‐C, based on efficacy parameters prespecified for European Medicines Agency ( EMA ) submission. Methods: Two randomised, double‐blind, multicentre Phase 3 trials investigated once‐daily linaclotide (290 μg) for 12 weeks (Trial 31) or 26 weeks (Trial 302) in patients with IBS‐C. Prespecified primary endpoints were the EMA‐recommended co‐primary endpoints: (i) 12‐week abdominal pain/discomfort responders [≥30% reduction in mean abdominal pain and/or discomfort score (11‐point scales), with neither worsening from baseline, for ≥6 weeks] and (ii) 12‐week IBS degree‐of‐relief responders (symptoms ‘considerably’ or ‘completely’ relieved for ≥6 weeks). Results: Overall, 803 (Trial 31) and 805 patients (Trial 302) were randomised. A significantly greater proportion of linaclotide‐treated vs. placebo‐treated patients were 12‐week abdominal pain/discomfort responders (Trial 31: 54.8% vs. 41.8%; Trial 302: 54.1% vs. 38.5%; P < 0.001) and IBS degree‐of‐relief responders (Trial 31: 37.0% vs. 18.5%; Trial 302: 39.4% vs. 16.6%; P < 0.0001). Similarly, significantly more linaclotide‐ vs. placebo‐treated patients were responders for ≥13 weeks in Trial 302 (abdominal pain/discomfort: 53.6% vs. 36.0%; IBS degree‐of‐relief: 37.2% vs. 16.9%; P < 0.0001). The proportion of sustained responders (co‐primary endpoint responders plus responders for ≥2 of the last 4 weeks of treatment) was also significantly greater with linaclotide vs. placebo in both trials ( P < 0.001). Conclusion: Linaclotide treatment significantly improved abdominal pain/discomfort and degree‐of‐relief of IBS‐C symptoms compared with placebo over 12 and 26 weeks. Trial registration: ClinicalTrials.gov (identifiers: NCT00948818 and NCT00938717).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/apt.12123

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 127

Metadata

Authors
Quigley, E. M. M., Tack, J., Chey, W. D., Rao, S. S., Fortea, J., Falques, M., Diaz, C., Shiff, S. J., Currie, M. G., & Johnston, J. M.
Venue
Alimentary Pharmacology & Therapeutics
Publisher
Wiley
Published
2012-11
Volume
37
Issue
1
Pages
49-61
ISSN
  • 0269-2813 (ISSN-L)
  • 1365-2036
OpenAlex
W1968228152
Cited by
127
References
10
FWCI
14.07
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.